Several large clinical trials have demonstrated that the improvement of BCVA >15 ETDRS letters has been achieved by anti-VEGF agents in 33-45% of patients with either type 1 or type 2 diabetes [8, 16, 17]. The gene discussed is VEGFA; the disease is type 2 diabetes mellitus.